The Case CCC Athymic Animal &Xenograft Core Facility includes two sites, one at CWRU and one at CCF. The Core is directed by Daniel Lindner and co-directed by Lili Liu. Case CCC members from 7 of the 8 research programs utilize the Core for their studies. In particular, the Cancer Cell Signaling, GU Malignancies, Hematopoietic Disorders, and Developmental Therapeutics Programs utilize the Core. The Core provides a facility for breeding and housing of athymic nude mice (NCRnu/nu), NOD-SCID mice, and other immunodeficient animals. The Core also provides pathogen-free facilities for experimentation using immunodeficient animal hosts and xenografts of human cell lines, human tumors, and normal human cells, in particular hematopoietic cells. The Core helps investigators design and perform experiments, tumor measurements, draw blood samples, and monitoring functions. Core staff maintain and monitor animals housed in the facility, and provide users with many services that facilitate research projects including transportation from one site to another, transportation to the animal imaging and radiation facilities, health reports, animal handling, and animal handling training. For individual investigator research, the Core teaches experimental techniques and performs experimental procedures. Investigators use mice in the facility for studies of human tumor xenografts to test anticancer drug effects on syngeneic murine tumor implants, to determine species-specific effect of cytokines and evaluate cytotoxic T cell (CTL) response to tumor associated antigens;to test oncogenicity of specific tumor genes on human tumor xenografts;and to perform small animal imaging to detect cancer size and location, as well as anticancer drug distribution and pharmacokinefic study in vivo. The Core has provided key support for studies investigating combination treatment of the protein tyrosine phosphatase (PTPase) inhibitors with agents that sensitize inhibitor resistant tumors in mouse models. Mouse tumor studies performed by the Core were pivotal to delineate the role and mechanism of action of oncogenic PTPases in malignant diseases. In addition. Xenograft studies were critical to study the growth inhibitory effects of apigenin;to determine whether pharmacologic intervention with apigenin has a direct growth inhibitory effect on human prostate tumors implanted in athymic nude mice;and to examine cell cycle regulatory molecules as precise molecular targets of apigenin action.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30CA043703-24
Application #
8765394
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Zhao, S; Sedwick, D; Wang, Z (2015) Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene 34:3885-94
Brubaker, Douglas; Difeo, Analisa; Chen, Yanwen et al. (2014) Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance. Pac Symp Biocomput :125-35
Dermawan, Josephine Kam Tai; Gurova, Katerina; Pink, John et al. (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-?B, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13:2203-14
Dabir, Snehal; Kluge, Amy; McColl, Karen et al. (2014) PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int J Cancer 134:1045-54
Yori, Jennifer L; Lozada, Kristen L; Seachrist, Darcie D et al. (2014) Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Res 74:4762-71
Sizemore, Gina M; Sizemore, Steven T; Seachrist, Darcie D et al. (2014) GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J Biol Chem 289:24102-13
Zapanta Rinonos, Serendipity; Rai, Urvashi; Vereb, Sydney et al. (2014) Sequential logic of polarity determination during the haploid-to-diploid transition in Saccharomyces cerevisiae. Eukaryot Cell 13:1393-402
Dotan, Efrat; Devarajan, Karthik; D'Silva, A James et al. (2014) Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clin Colorectal Cancer 13:192-8
Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Davuluri, Gangarao et al. (2014) Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J 28:2260-71
Dabir, Snehal; Babakoohi, Shahab; Kluge, Amy et al. (2014) RET mutation and expression in small-cell lung cancer. J Thorac Oncol 9:1316-23

Showing the most recent 10 out of 975 publications